Modulation of Amphetamine-Induced Dopamine Release by Group II Metabotropic Glutamate Receptor Agonist LY354740 in Non-Human Primates Studied with Positron Emission Tomography

[1]  M. Laruelle.  Dopamine Transmission in the Schizophrenic Brain , 2007 .

[2]  A. Denman,et al.  Schizophrenia (2nd edn) , 2004, British Journal of Psychiatry.

[3]  B. V. Berckel.  Glutamate and Schizophrenia , 2003 .

[4]  Nicola Pavese,et al.  Endogenous dopamine release after pharmacological challenges in Parkinson's disease , 2003, Annals of neurology.

[5]  Stephan Heckers,et al.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. , 2003, Pharmacology & therapeutics.

[6]  J. Hirvonen,et al.  Ketamine does not decrease striatal dopamine D2 receptor binding in man , 2002, Psychopharmacology.

[7]  D. Schoepp.  Control of neurotransmitter release by metabotropic glutamate receptors , 2002, European Neuropsychopharmacology.

[8]  Hideo Tsukada,et al.  Comparative effects of methamphetamine and nicotine on the striatal [11C]raclopride binding in unanesthetized monkeys , 2002, Synapse.

[9]  B. Moghaddam,et al.  NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys , 2002, Synapse.

[10]  R. V. Van Heertum,et al.  NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans , 2002, Synapse.

[11]  Nathalie Ginovart,et al.  PET study of the [11C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  M. Laruelle,et al.  Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.

[13]  B. Moghaddam,et al.  Target‐Specific Glutamatergic Regulation of Dopamine Neurons in the Ventral Tegmental Area , 2000, Journal of neurochemistry.

[14]  L. Mao,et al.  Activation of group III metabotropic glutamate receptors inhibits basal and amphetamine-stimulated dopamine release in rat dorsal striatum: an in vivo microdialysis study. , 2000, European journal of pharmacology.

[15]  N. Harada,et al.  Cholinergic Neuronal Modulation Alters Dopamine D2Receptor Availability In Vivo by Regulating Receptor Affinity Induced by Facilitated Synaptic Dopamine Turnover: Positron Emission Tomography Studies with Microdialysis in the Conscious Monkey Brain , 2000, The Journal of Neuroscience.

[16]  L. Mao,et al.  Distinct inhibition of acute cocaine-stimulated motor activity following microinjection of a group III metabotropic glutamate receptor agonist into the dorsal striatum of rats , 2000, Pharmacology Biochemistry and Behavior.

[17]  S. Sesack,et al.  Projections from the Rat Prefrontal Cortex to the Ventral Tegmental Area: Target Specificity in the Synaptic Associations with Mesoaccumbens and Mesocortical Neurons , 2000, The Journal of Neuroscience.

[18]  M. Laruelle.  Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  D Hell,et al.  Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. , 2000, Journal of psychiatric research.

[20]  Hideo Tsukada,et al.  Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain , 1999, Brain Research.

[21]  A. Carlsson,et al.  Neurotransmitter interactions in schizophrenia—therapeutic implications , 1999, Biological Psychiatry.

[22]  D. Jane,et al.  Pharmacological agents acting at subtypes of metabotropic glutamate receptors , 1999, Neuropharmacology.

[23]  D. Wong,et al.  GBR12909 attenuates amphetamine‐induced striatal dopamine release as measured by [11C]raclopride continuous infusion PET scans , 1999, Synapse.

[24]  N. Harada,et al.  Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [ 11 C ]raclopride?: PET studies combined with microdialysis in conscious monkeys , 1999, Brain Research.

[25]  J. Pin,et al.  New perspectives for the development of selective metabotropic glutamate receptor ligands. , 1999, European journal of pharmacology.

[26]  J. Grutsch,et al.  Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. , 1999, Journal of medicinal chemistry.

[27]  R. Roth,et al.  The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.

[28]  M Laruelle,et al.  Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.

[29]  M. Santi,et al.  N‐acetylaspartylglutamate activates cyclic AMP‐coupled metabotropic glutamate receptors in cerebellar astrocytes , 1998, Glia.

[30]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[31]  A. Malhotra,et al.  Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.

[32]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[33]  D. Schoepp,et al.  Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. , 1998, The Journal of pharmacology and experimental therapeutics.

[34]  M. Daube-Witherspoon,et al.  Quantitative functional brain imaging with positron emission tomography , 1998 .

[35]  M. Laruelle,et al.  Imaging Receptor Occupancy by Endogenous Transmitters in Humans , 1998 .

[36]  N. Volkow,et al.  Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects , 1998, Neuropsychopharmacology.

[37]  G Brix,et al.  Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  D. Schoepp,et al.  In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats , 1997, Neuroscience Letters.

[39]  J. Neale,et al.  N‐Acetylaspartylglutamate Selectively Activates mGluR3 Receptors in Transfected Cells , 1997, Journal of neurochemistry.

[40]  D. Schoepp,et al.  Design, Synthesis, and Pharmacological Characterization of (+)-2- Aminobicyclo(3.1.0)hexane-2,6-dicarboxylic Acid (LY354740): A Potent, Selective, and Orally Active Group 2 Metabotropic Glutamate Receptor Agonist Possessing Anticonvulsant and Anxiolytic Properties. , 1997 .

[41]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[42]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Schoepp,et al.  Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. , 1997, Journal of medicinal chemistry.

[44]  D. Schoepp,et al.  LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors , 1997, Neuropharmacology.

[45]  P B Hoffer,et al.  Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.

[46]  E. Abercrombie,et al.  Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats , 1996, Brain Research Bulletin.

[47]  B. Bunney,et al.  Effects of Lesions in the Medial Prefrontal Cortex on the Activity of Midbrain Dopamine Neurons , 1996, Neuropsychopharmacology.

[48]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  F. Nicoletti,et al.  Interaction Between A1 Adenosine and Class II Metabotropic Glutamate Receptors in the Regulation of Purine and Glutamate Release from Rat Hippocampal Slices , 1996, Journal of neurochemistry.

[50]  B. Moghaddam,et al.  The Prefrontal Cortex Regulates the Basal Release of Dopamine in the Limbic Striatum: An Effect Mediated by Ventral Tegmental Area , 1996, Journal of neurochemistry.

[51]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[52]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[53]  J. Brotchie,et al.  Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. , 1995, European journal of pharmacology.

[54]  Robert B. Innis,et al.  Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  S. Zoghbi,et al.  Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.

[56]  S. Nakanishi,et al.  Molecular diversity and functions of glutamate receptors. , 1994, Annual review of biophysics and biomolecular structure.

[57]  F. Gonon,et al.  Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo , 1993, Neuroscience Letters.

[58]  O. Mamer,et al.  Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. , 1993, Biological mass spectrometry.

[59]  D. Jewett,et al.  A simple synthesis of [11C]methyl triflate. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[60]  J. Mazziotta,et al.  Rapid Automated Algorithm for Aligning and Reslicing PET Images , 1992, Journal of computer assisted tomography.

[61]  D. Jewett.  A Simple Synthesis of (llC)Methyl Triflate , 1992 .

[62]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[63]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[64]  P. Groves,et al.  Burst firing induced in midbrain dopamine neurons by stimulation of the medial prefrontal and anterior cingulate cortices , 1988, Brain Research.

[65]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[66]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[67]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[68]  P. Duvaldestin.  Pharmacokinetics in Intravenous Anaesthetic Practice , 1981, Clinical pharmacokinetics.

[69]  A Carlsson,et al.  Antipsychotic drugs, neurotransmitters, and schizophrenia. , 1978, The American journal of psychiatry.

[70]  Kenneth Levenberg.  A METHOD FOR THE SOLUTION OF CERTAIN NON – LINEAR PROBLEMS IN LEAST SQUARES , 1944 .

[71]  T D Cradduck,et al.  National electrical manufacturers association , 1983, Journal of the A.I.E.E..